Intranasal fluorinated nano-adjuvant orchestrates CCL2-driven pre-DC recruitment and transmucosal antigen delivery to elicit long-term immunity against influenza
Journal of Controlled Release · 2026-08 · 396 · 115102
DOI: 10.1016/j.jconrel.2026.115102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-08. Verfasst von Lingli Shen und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou 450046, C…. Hauptthemen laut MEDLINE: Dendritic Cells, Influenza Vaccines, Chemokine CCL2, Orthomyxoviridae Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Intranasal vaccines offer the unique advantage of inducing mucosal immunity to prevent influenza infection at the portal of entry. However, its efficacy is compromised by two major barriers, limited reservoir of resident conventional dendritic cells (cDCs) for antigen presentation and poor transmucosal delivery of antigen. Herein, we engineered a versatile intranasal vaccine nano-adjuvant, mannose-modified fluorinated PEI (MFPEI), to synergistically overcome these challenges. MFPEI combined fluoroalkane-mediated mucus penetration, mannose-assisted DCs targeting, and TLR4/NF-κB pathway activation. The fluorinated backbone endowed MFPEI/HA with hydrophobic and lipophobic characteristics, minimizing mucin entrapment and significantly enhancing antigen penetration across the mucosal layer. Concurrently, MFPEI activated TLR4/NF-κB signaling pathway in DCs, promoting CCL2 secretion and subsequently facilitating precursor dendritic cells (pre-DCs) recruitment via CCR2-CCL2 pathway to replenish the nasal cDCs network. This dual strategy maximized antigen uptake and presentation, culminating in potent and durable mucosal and systemic immunity that conferred complete immune protection against influenza infection. Our study establishes MFPEI as a promising nano-adjuvant platform for next-generation intranasal vaccines against influenza and other respiratory pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou 450046, China.
- College of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou 450046, China; Longhu Laboratory of Advanced Immunology, Zhengzhou 450046, Chin…
- College of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou 450046, China. Electronic address: hhe@henau.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Shen, L., Yang, H., Zhou, H., Liu, Z., Duan, L., Wang, S., Niu, Q., Wu, Y., Zhang, G., & He, H. (2026). Intranasal fluorinated nano-adjuvant orchestrates CCL2-driven pre-DC recruitment and transmucosal antigen delivery to elicit long-term immunity against influenza. Journal of Controlled Release, 396, 115102. https://doi.org/10.1016/j.jconrel.2026.115102
Vancouver
Shen L, Yang H, Zhou H, Liu Z, Duan L, Wang S, et al. Intranasal fluorinated nano-adjuvant orchestrates CCL2-driven pre-DC recruitment and transmucosal antigen delivery to elicit long-term immunity against influenza. Journal of Controlled Release. 2026;396:115102. doi:10.1016/j.jconrel.2026.115102
BibTeX
@article{Shen2026,
author = {Shen, Lingli and Yang, Haoxiang and Zhou, Hengqi and Liu, Ziyang and Duan, Laitong and Wang, Shuqi and Niu, Qun and Wu, Yanan and Zhang, Gaiping and He, Hua},
title = {Intranasal fluorinated nano-adjuvant orchestrates CCL2-driven pre-DC recruitment and transmucosal antigen delivery to elicit long-term immunity against influenza},
journal = {Journal of Controlled Release},
year = {2026},
volume = {396},
pages = {115102},
doi = {10.1016/j.jconrel.2026.115102}
}
EUVIMED